These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinicopathological and immunohistochemical evaluation of oral and oropharyngeal squamous cell carcinoma in Chilean population. Rivera C; González-Arriagada WA; Loyola-Brambilla M; de Almeida OP; Coletta RD; Venegas B Int J Clin Exp Pathol; 2014; 7(9):5968-77. PubMed ID: 25337241 [TBL] [Abstract][Full Text] [Related]
3. Salivary Tumour Necrosis Factor-α as a Biomarker in Oral Leukoplakia and Oral Squamous Cell Carcinoma. G D; Nandan SRK; Kulkarni PG Asian Pac J Cancer Prev; 2019 Jul; 20(7):2087-2093. PubMed ID: 31350970 [TBL] [Abstract][Full Text] [Related]
4. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma. Yang CZ; Ma J; Luo QQ; Neskey DM; Zhu DW; Liu Y; Myers JN; Zhang CP; Zhang ZY; Zhong LP J Oral Pathol Med; 2014 Jan; 43(1):28-34. PubMed ID: 23710769 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of saliva and plasma cytokine biomarkers in patients with oral squamous cell carcinoma. Lee LT; Wong YK; Hsiao HY; Wang YW; Chan MY; Chang KW Int J Oral Maxillofac Surg; 2018 Jun; 47(6):699-707. PubMed ID: 29174861 [TBL] [Abstract][Full Text] [Related]
6. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer. Ajona D; Razquin C; Pastor MD; Pajares MJ; Garcia J; Cardenal F; Fleischhacker M; Lozano MD; Zulueta JJ; Schmidt B; Nadal E; Paz-Ares L; Montuenga LM; Pio R PLoS One; 2015; 10(3):e0119878. PubMed ID: 25799154 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of salivary endothelin-1 levels in oral squamous cell carcinoma and oral leukoplakia. Hoffmann RR; Yurgel LS; Campos MM Regul Pept; 2011 Jan; 166(1-3):55-8. PubMed ID: 20727373 [TBL] [Abstract][Full Text] [Related]
8. Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. Ajona D; Pajares MJ; Corrales L; Perez-Gracia JL; Agorreta J; Lozano MD; Torre W; Massion PP; de-Torres JP; Jantus-Lewintre E; Camps C; Zulueta JJ; Montuenga LM; Pio R J Natl Cancer Inst; 2013 Sep; 105(18):1385-93. PubMed ID: 23940286 [TBL] [Abstract][Full Text] [Related]
9. Significance of Expression of Complement C4d in Esophageal Squamous Cell Carcinoma. Kikuchi M; Nakajima M; Muroi H; Takahashi M; Itoh J; Yamaguchi S; Sasaki K; Kato H Anticancer Res; 2016 Sep; 36(9):4553-7. PubMed ID: 27630295 [TBL] [Abstract][Full Text] [Related]
10. [Expression of Prion protein and its clinical significance in oral squamous cells carcinoma and oral leukoplakia]. Zhang J; Zeng Y; Zheng J; Xu J Zhonghua Kou Qiang Yi Xue Za Zhi; 2013 Dec; 48(12):752-4. PubMed ID: 24495728 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of p53 and p63 in oral squamous cell carcinoma, oral leukoplakia, and oral submucous fibrosis. Varun BR; Ranganathan K; Rao UK; Joshua E J Investig Clin Dent; 2014 Aug; 5(3):214-9. PubMed ID: 23776093 [TBL] [Abstract][Full Text] [Related]
12. Salivary metabolite signatures of oral cancer and leukoplakia. Wei J; Xie G; Zhou Z; Shi P; Qiu Y; Zheng X; Chen T; Su M; Zhao A; Jia W Int J Cancer; 2011 Nov; 129(9):2207-17. PubMed ID: 21190195 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of enzymatic and non-enzymatic antioxidant status and biomarkers of oxidative stress in saliva of patients with oral squamous cell carcinoma and oral leukoplakia: a pilot study. Babiuch K; Bednarczyk A; Gawlik K; Pawlica-Gosiewska D; Kęsek B; Darczuk D; Stępień P; Chomyszyn-Gajewska M; Kaczmarzyk T Acta Odontol Scand; 2019 Aug; 77(6):408-418. PubMed ID: 30857448 [No Abstract] [Full Text] [Related]
14. Salivary mRNA markers having the potential to detect oral squamous cell carcinoma segregated from oral leukoplakia with dysplasia. Michailidou E; Tzimagiorgis G; Chatzopoulou F; Vahtsevanos K; Antoniadis K; Kouidou S; Markopoulos A; Antoniades D Cancer Epidemiol; 2016 Aug; 43():112-8. PubMed ID: 27263493 [TBL] [Abstract][Full Text] [Related]
15. Analysis of tumor marker CA 125 in saliva of normal and oral squamous cell carcinoma patients: a comparative study. Balan JJ; Rao RS; Premalatha BR; Patil S J Contemp Dent Pract; 2012 Sep; 13(5):671-5. PubMed ID: 23250173 [TBL] [Abstract][Full Text] [Related]
16. Expression of Fas and Fas-ligand and analysis of argyrophilic nucleolar organizer regions in squamous cell carcinoma: relationships with tumor stage and grade, and apoptosis. Guler N; Uckan S; Celik I; Oznurlu Y; Uckan D Int J Oral Maxillofac Surg; 2005 Dec; 34(8):900-6. PubMed ID: 15907374 [TBL] [Abstract][Full Text] [Related]
17. Serum metabolomics in oral leukoplakia and oral squamous cell carcinoma. Sridharan G; Ramani P; Patankar S J Cancer Res Ther; 2017; 13(3):556-561. PubMed ID: 28862226 [TBL] [Abstract][Full Text] [Related]
18. Increased plasma and salivary cortisol levels in patients with oral cancer and their association with clinical stage. Bernabé DG; Tamae AC; Miyahara GI; Sundefeld ML; Oliveira SP; Biasoli ÉR J Clin Pathol; 2012 Oct; 65(10):934-9. PubMed ID: 22734006 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of salivary and serum lipid peroxidation, and glutathione in oral leukoplakia and oral squamous cell carcinoma. Metgud R; Bajaj S J Oral Sci; 2014 Jun; 56(2):135-42. PubMed ID: 24930750 [TBL] [Abstract][Full Text] [Related]
20. Detection of survivin, carcinoembryonic antigen and ErbB2 level in oral squamous cell carcinoma patients. Li SX; Yang YQ; Jin LJ; Cai ZG; Sun Z Cancer Biomark; 2016; 17(4):377-382. PubMed ID: 27662323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]